博拓生物
(688767)
| 流通市值：46.06亿 | | | 总市值：46.06亿 |
| 流通股本：1.07亿 | | | 总股本：1.07亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,627,567,018.15 | 1,590,964,931.16 | 1,610,085,475.64 | 1,565,595,867.47 |
| 应收票据及应收账款 | 67,092,116.03 | 97,460,473.23 | 83,185,165.87 | 68,531,418.69 |
| 应收账款 | 67,092,116.03 | 97,460,473.23 | 83,185,165.87 | 68,531,418.69 |
| 预付款项 | 4,978,992.87 | 1,717,459.85 | 1,543,183.91 | 1,271,885.94 |
| 其他应收款合计 | 1,544,951.54 | 4,267,075.03 | 1,480,711.18 | 44,335,769.36 |
| 存货 | 75,115,268.21 | 73,401,089.46 | 76,257,370.96 | 80,459,595.31 |
| 一年内到期的非流动资产 | - | - | - | 0 |
| 其他流动资产 | 44,234,433.38 | 49,853,863.54 | 61,345,177.52 | 1,884,165.67 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,820,532,780.18 | 1,877,922,689.1 | 1,834,897,085.08 | 1,862,078,702.44 |
| 非流动资产: | | | | |
| 长期股权投资 | 8,605,449.13 | 9,298,772.71 | 2,203,087.57 | 2,377,090.28 |
| 投资性房地产 | 4,286,678.78 | 4,343,419.24 | 4,730,192.8 | 4,798,618.52 |
| 固定资产 | 316,027,648.03 | 321,583,129.9 | 371,552,109.26 | 378,167,990.77 |
| 在建工程 | 96,857,550.34 | 87,225,128.09 | 97,248,733.73 | 49,941,029.95 |
| 使用权资产 | - | 0 | 21,979.4 | 61,979.4 |
| 无形资产 | 273,963,986.19 | 275,159,946.95 | 204,311,221.91 | 205,802,521.91 |
| 长期待摊费用 | - | - | 26,778.78 | 54,470.13 |
| 递延所得税资产 | 11,422,021.04 | 11,796,847 | 10,286,009.38 | 12,925,735.57 |
| 其他非流动资产 | 12,041,130 | 14,802,107.92 | 4,451,102.84 | 2,757,750 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 723,204,463.51 | 724,209,351.81 | 694,831,215.67 | 656,887,186.53 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,543,737,243.69 | 2,602,132,040.91 | 2,529,728,300.75 | 2,518,965,888.97 |
| 流动负债: | | | | |
| 短期借款 | 1,073,448.06 | 440,516.15 | 299,027.2 | 522,443.97 |
| 应付票据及应付账款 | 42,610,289.36 | 56,449,025.72 | 59,443,976.79 | 60,213,838.06 |
| 应付账款 | 42,610,289.36 | 56,449,025.72 | 59,443,976.79 | 60,213,838.06 |
| 合同负债 | 12,953,806.4 | 7,392,913.16 | 46,681,502.68 | 41,529,746.29 |
| 应付职工薪酬 | 7,730,807.3 | 15,246,027.26 | 14,166,901.94 | 12,277,288.36 |
| 应交税费 | 2,766,169.01 | 4,535,834.55 | 2,048,997.54 | 5,249,190.44 |
| 其他应付款合计 | 41,164,123.92 | 94,366,846.65 | 16,949,817.68 | 19,832,936.48 |
| 应付股利 | - | 53,208,333.5 | - | - |
| 一年内到期的非流动负债 | - | 0 | 445,276.47 | 1,128,308.7 |
| 其他流动负债 | 461,802.39 | 185,860.06 | 268,028.11 | 204,948.79 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 108,760,446.44 | 178,617,023.55 | 140,303,528.41 | 140,958,701.09 |
| 非流动负债: | | | | |
| 递延收益 | 10,747,223.29 | 11,168,841.53 | 10,653,558.66 | 10,996,250.6 |
| 递延所得税负债 | - | 0 | - | 708,330.62 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 10,747,223.29 | 11,168,841.53 | 10,653,558.66 | 11,704,581.22 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 119,507,669.73 | 189,785,865.08 | 150,957,087.07 | 152,663,282.31 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 106,666,667 | 106,666,667 | 106,666,667 | 106,666,667 |
| 资本公积 | 794,599,234.49 | 790,452,036.71 | 813,332,050.99 | 813,332,050.99 |
| 减:库存股 | 31,608,764.8 | 31,608,764.8 | 57,944,777.24 | 56,934,967.8 |
| 其他综合收益 | 1,022,848.52 | 939,567.53 | -2,201,509.16 | 566,686.55 |
| 盈余公积 | 53,333,333.5 | 53,333,333.5 | 53,333,333.5 | 53,333,333.5 |
| 未分配利润 | 1,498,425,695.97 | 1,489,693,267.07 | 1,462,597,850.95 | 1,445,561,226.77 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,422,439,014.68 | 2,409,476,107.01 | 2,375,783,616.04 | 2,362,524,997.01 |
| 少数股东权益 | 1,790,559.28 | 2,870,068.82 | 2,987,597.64 | 3,777,609.65 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,424,229,573.96 | 2,412,346,175.83 | 2,378,771,213.68 | 2,366,302,606.66 |
| 负债和股东权益合计 | 2,543,737,243.69 | 2,602,132,040.91 | 2,529,728,300.75 | 2,518,965,888.97 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |